TY - JOUR
T1 - Consensus on the development of vaccines against naturally acquired melioidosis
AU - Limmathurotsakul, Direk
AU - Funnell, Simon
AU - Torres, Alfredo G.
AU - Morici, Lisa A.
AU - Brett, Paul J.
AU - Dunachie, Susanna
AU - Atkins, Timothy
AU - Altmann, Daniel M.
AU - Bancroft, Gregory
AU - Peacock, Sharon
N1 - Publisher Copyright:
© 2015, Marmara University. All rights reserved.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Several candidates for a vaccine against Burkholderia pseudomallei, the causal bacterium of melioidosis, have been developed, and a rational approach is now needed to select and advance candidates for testing in relevant nonhuman primate models and in human clinical trials. Development of such a vaccine was the topic of a meeting in the United Kingdom in March 2014 attended by international candidate vaccine developers, researchers, and government health officials. The focus of the meeting was advancement of vaccines for prevention of natural infection, rather than for protection from the organism’s known potential for use as a biological weapon. A direct comparison of candidate vaccines in well-characterized mouse models was proposed. Knowledge gaps requiring further research were identified. Recommendations were made to accelerate the development of an effective vaccine against melioidosis.
AB - Several candidates for a vaccine against Burkholderia pseudomallei, the causal bacterium of melioidosis, have been developed, and a rational approach is now needed to select and advance candidates for testing in relevant nonhuman primate models and in human clinical trials. Development of such a vaccine was the topic of a meeting in the United Kingdom in March 2014 attended by international candidate vaccine developers, researchers, and government health officials. The focus of the meeting was advancement of vaccines for prevention of natural infection, rather than for protection from the organism’s known potential for use as a biological weapon. A direct comparison of candidate vaccines in well-characterized mouse models was proposed. Knowledge gaps requiring further research were identified. Recommendations were made to accelerate the development of an effective vaccine against melioidosis.
UR - http://www.scopus.com/inward/record.url?scp=84981749578&partnerID=8YFLogxK
U2 - 10.3201/eid2106.141480
DO - 10.3201/eid2106.141480
M3 - Article
C2 - 25992835
AN - SCOPUS:84981749578
SN - 1080-6040
VL - 21
SP - e1-e7
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 6
ER -